Terns Pharmaceuticals (TERN) EBIT (2020 - 2023)
Historic EBIT for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.0 million.
- Terns Pharmaceuticals' EBIT fell 2488.71% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.0 million, marking a year-over-year decrease of 4512.08%. This contributed to the annual value of -$101.9 million for FY2024, which is 66.99% up from last year.
- Per Terns Pharmaceuticals' latest filing, its EBIT stood at -$21.0 million for Q4 2023, which was down 2488.71% from -$29.7 million recorded in Q3 2023.
- Terns Pharmaceuticals' EBIT's 5-year high stood at -$8.7 million during Q3 2020, with a 5-year trough of -$29.7 million in Q3 2023.
- In the last 4 years, Terns Pharmaceuticals' EBIT had a median value of -$13.9 million in 2021 and averaged -$14.9 million.
- Per our database at Business Quant, Terns Pharmaceuticals' EBIT plummeted by 397.86% in 2022 and then plummeted by 7180.78% in 2023.
- Quarter analysis of 4 years shows Terns Pharmaceuticals' EBIT stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022, then dropped by 24.89% to -$21.0 million in 2023.
- Its EBIT was -$21.0 million in Q4 2023, compared to -$29.7 million in Q3 2023 and -$17.8 million in Q2 2023.